Company Description

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain.

Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy.

In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases.

Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

Serina Therapeutics Inc

Country	United States
Founded	2017
IPO Date	Nov 29, 2018
Industry	Biotechnology
Sector	Healthcare
Employees	9
CEO	Steven A. Ledger

Contact Details

Address: 601 Genome Way, Suite 2001 Huntsville, Alabama 35806 United States
Phone	(256) 327-9630

Stock Details

Ticker Symbol	SER
Exchange	NYSEAMERICAN
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001708599
ISIN Number	US81751A1088
Employer ID	82-1436829
SIC Code	2834

Key Executives

Name	Position
Steven A. Ledger	Interim Chief Executive Officer
Dr. J. Milton Harris Ph.D.	Co-Founder and Chairman of The Board
Dr. Randall W. Moreadith M.D., Ph.D.	President and Director
Dr. Michael D. Bentley Ph.D.	Co-Founder, Chief Scientific Officer and Director
Dr. Tacey Viegas	Chief Operating Officer

Latest SEC Filings

Date	Type	Title
Jun 17, 2024	S-1/A	[Amend] General form for registration of securities under the Securities Act of 1933
Jun 17, 2024	S-8	Securities to be offered to employees in employee benefit plans
Jun 10, 2024	8-K	Current Report
May 14, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
May 3, 2024	S-1	General form for registration of securities under the Securities Act of 1933
May 3, 2024	8-K	Current Report
Apr 17, 2024	8-K	Current Report
Apr 3, 2024	SC 13D	General statement of acquisition of beneficial ownership
Apr 1, 2024	8-K	Current Report

View All SEC Filings